Comments
Loading...

Viridian Therapeutics Analyst Ratings

VRDNNASDAQ
Logo brought to you by Benzinga Data
$14.44
-0.23-1.57%
At close: -
$14.44
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$61.00
Lowest Price Target1
$20.00
Consensus Price Target1
$38.73

Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN | Benzinga

Viridian Therapeutics Inc has a consensus price target of $38.73 based on the ratings of 18 analysts. The high is $61 issued by BTIG on September 26, 2024. The low is $20 issued by B. Riley Securities on May 9, 2024. The 3 most-recent analyst ratings were released by Needham, Wells Fargo, and RBC Capital on January 7, 2025, December 19, 2024, and December 17, 2024, respectively. With an average price target of $37.33 between Needham, Wells Fargo, and RBC Capital, there's an implied 158.54% upside for Viridian Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct 24
4
Nov 24
4
1
Dec 24
1
Jan
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
Wells Fargo
RBC Capital
HC Wainwright & Co.
BTIG

1calculated from analyst ratings

Analyst Ratings for Viridian Therapeutics

Buy NowGet Alert
01/07/2025Buy Now163.16%Needham
Serge Belanger70%
$38 → $38ReiteratesBuy → BuyGet Alert
12/19/2024Buy Now86.98%Wells Fargo
Derek Archila58%
→ $27DowngradeOverweight → Equal-WeightGet Alert
12/17/2024Buy Now225.48%RBC Capital
Gregory Renza47%
$44 → $47MaintainsOutperformGet Alert
12/17/2024Buy Now135.46%HC Wainwright & Co.
Douglas Tsao52%
$34 → $34ReiteratesBuy → BuyGet Alert
12/16/2024Buy Now135.46%HC Wainwright & Co.
Douglas Tsao52%
$34 → $34ReiteratesBuy → BuyGet Alert
12/05/2024Buy Now204.71%RBC Capital
Gregory Renza47%
$44 → $44ReiteratesOutperform → OutperformGet Alert
11/25/2024Buy Now163.16%Needham
Serge Belanger70%
$38 → $38ReiteratesBuy → BuyGet Alert
11/25/2024Buy NowTD Cowen
Joseph Thome34%
Initiates → BuyGet Alert
11/14/2024Buy Now135.46%HC Wainwright & Co.
Douglas Tsao52%
$27 → $34MaintainsBuyGet Alert
11/13/2024Buy Now163.16%Needham
Serge Belanger70%
$38 → $38ReiteratesBuy → BuyGet Alert
10/28/2024Buy Now163.16%Needham
Serge Belanger70%
$38 → $38ReiteratesBuy → BuyGet Alert
09/26/2024Buy Now322.44%BTIG
Julian Harrison41%
$56 → $61MaintainsBuyGet Alert
09/19/2024Buy Now204.71%RBC Capital
Gregory Renza47%
$44 → $44ReiteratesOutperform → OutperformGet Alert
09/13/2024Buy Now204.71%RBC Capital
Gregory Renza47%
$35 → $44MaintainsOutperformGet Alert
09/12/2024Buy Now114.68%Goldman Sachs
Richard Law45%
$25 → $31MaintainsBuyGet Alert
09/11/2024Buy Now163.16%Needham
Serge Belanger70%
$30 → $38MaintainsBuyGet Alert
09/10/2024Buy Now86.98%HC Wainwright & Co.
Douglas Tsao52%
$27 → $27ReiteratesBuy → BuyGet Alert
09/10/2024Buy Now287.81%BTIG
Julian Harrison41%
$46 → $56MaintainsBuyGet Alert
08/30/2024Buy Now107.76%Needham
Serge Belanger70%
$30 → $30ReiteratesBuy → BuyGet Alert
08/28/2024Buy Now142.38%RBC Capital
Gregory Renza47%
$35 → $35ReiteratesOutperform → OutperformGet Alert
08/15/2024Buy Now86.98%HC Wainwright & Co.
Douglas Tsao52%
$27 → $27ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now93.91%Oppenheimer
Leland Gershell69%
$31 → $28ReiteratesOutperform → OutperformGet Alert
07/29/2024Buy Now190.86%Wedbush
Laura Chico47%
$42 → $42ReiteratesOutperform → OutperformGet Alert
07/16/2024Buy Now86.98%HC Wainwright & Co.
Douglas Tsao52%
$27 → $27ReiteratesBuy → BuyGet Alert
06/11/2024Buy NowWolfe Research
Andy Chen37%
Initiates → OutperformGet Alert
06/11/2024Buy Now107.76%Needham
Serge Belanger70%
$30 → $30ReiteratesBuy → BuyGet Alert
06/06/2024Buy Now59.28%Goldman Sachs
Richard Law45%
→ $23Initiates → BuyGet Alert
05/09/2024Buy Now107.76%Needham
Serge Belanger70%
$30 → $30ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now86.98%HC Wainwright & Co.
Douglas Tsao52%
$37 → $27MaintainsBuyGet Alert
05/09/2024Buy Now114.68%Oppenheimer
Leland Gershell69%
$36 → $31MaintainsOutperformGet Alert
05/09/2024Buy NowLadenburg Thalmann
Michael Higgins47%
DowngradeBuy → NeutralGet Alert
05/09/2024Buy Now38.5%B. Riley Securities
Kalpit Patel38%
$25 → $20DowngradeBuy → NeutralGet Alert
03/21/2024Buy Now73.13%B. Riley Securities
Kalpit Patel38%
$29 → $25MaintainsBuyGet Alert
03/20/2024Buy Now107.76%Needham
Serge Belanger70%
$30 → $30MaintainsBuyGet Alert
02/29/2024Buy Now156.23%HC Wainwright & Co.
Douglas Tsao52%
$37 → $37ReiteratesBuy → BuyGet Alert
02/28/2024Buy Now107.76%Needham
Serge Belanger70%
$30 → $30ReiteratesBuy → BuyGet Alert
02/28/2024Buy Now177.01%Wedbush
Laura Chico47%
$39 → $40MaintainsOutperformGet Alert
12/19/2023Buy Now149.31%Oppenheimer
Leland Gershell69%
$35 → $36MaintainsOutperformGet Alert
12/18/2023Buy Now156.23%HC Wainwright & Co.
Douglas Tsao52%
$37 → $37ReiteratesBuy → BuyGet Alert
12/14/2023Buy Now142.38%RBC Capital
Gregory Renza47%
$35 → $35ReiteratesOutperform → OutperformGet Alert
12/04/2023Buy Now156.23%Wedbush
Laura Chico47%
→ $37ReiteratesOutperform → OutperformGet Alert
11/14/2023Buy Now142.38%RBC Capital
Gregory Renza47%
→ $35ReiteratesOutperform → OutperformGet Alert
11/14/2023Buy Now163.16%JMP Securities
Jason Butler55%
$42 → $38MaintainsMarket OutperformGet Alert
10/31/2023Buy Now142.38%RBC Capital
Gregory Renza47%
$44 → $35MaintainsOutperformGet Alert
10/31/2023Buy Now156.23%Wedbush
Laura Chico47%
$46 → $37MaintainsOutperformGet Alert
10/30/2023Buy Now107.76%Needham
Serge Belanger70%
$40 → $30MaintainsBuyGet Alert
09/13/2023Buy Now177.01%Stifel
Alex Thompson44%
→ $40ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now218.56%Wedbush
Laura Chico47%
→ $46ReiteratesOutperform → OutperformGet Alert
08/10/2023Buy Now156.23%HC Wainwright & Co.
Douglas Tsao52%
$40 → $37MaintainsBuyGet Alert
08/10/2023Buy Now177.01%Needham
Serge Belanger70%
$47 → $40MaintainsBuyGet Alert
08/09/2023Buy Now190.86%JMP Securities
Jason Butler55%
$44 → $42MaintainsMarket OutperformGet Alert
08/09/2023Buy Now204.71%RBC Capital
Gregory Renza47%
→ $44ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now170.08%Wells Fargo$46 → $39MaintainsOverweightGet Alert
08/09/2023Buy Now142.38%Oppenheimer
Leland Gershell69%
$40 → $35MaintainsOutperformGet Alert
07/11/2023Buy Now211.63%Wedbush
Laura Chico47%
$48 → $45MaintainsOutperformGet Alert
07/11/2023Buy Now204.71%RBC Capital
Gregory Renza47%
→ $44ReiteratesOutperform → OutperformGet Alert
07/11/2023Buy Now204.71%JMP Securities
Jason Butler55%
→ $44ReiteratesMarket Outperform → Market OutperformGet Alert
07/11/2023Buy Now225.48%Needham
Serge Belanger70%
→ $47ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now177.01%HC Wainwright & Co.
Douglas Tsao52%
→ $40ReiteratesBuy → BuyGet Alert
06/14/2023Buy Now218.56%BTIG
Julian Harrison41%
→ $46Initiates → BuyGet Alert
06/14/2023Buy Now253.19%Credit Suisse
Tiago Fauth42%
→ $51Assumes → OutperformGet Alert
05/30/2023Buy Now204.71%RBC Capital
Gregory Renza47%
→ $44Initiates → OutperformGet Alert
05/10/2023Buy Now177.01%Oppenheimer
Leland Gershell69%
$45 → $40MaintainsOutperformGet Alert
05/10/2023Buy Now232.41%Wedbush
Laura Chico47%
$46 → $48MaintainsOutperformGet Alert
05/10/2023Buy Now253.19%Credit Suisse
Tiago Fauth42%
→ $51Reiterates → OutperformGet Alert
05/10/2023Buy Now204.71%JMP Securities
Jason Butler55%
$46 → $44MaintainsMarket OutperformGet Alert
05/10/2023Buy Now177.01%HC Wainwright & Co.
Douglas Tsao52%
→ $40Reiterates → BuyGet Alert
04/17/2023Buy Now218.56%Wells Fargo → $46Initiates → OverweightGet Alert
04/10/2023Buy Now225.48%Needham
Serge Belanger70%
→ $47Reiterates → BuyGet Alert
03/30/2023Buy Now239.34%Stifel
Alex Thompson44%
→ $49Initiates → BuyGet Alert
03/09/2023Buy Now177.01%Ladenburg Thalmann
Michael Higgins47%
→ $40Reiterates → BuyGet Alert
03/09/2023Buy Now177.01%HC Wainwright & Co.
Douglas Tsao52%
$35 → $40MaintainsBuyGet Alert
02/07/2023Buy Now142.38%HC Wainwright & Co.
Douglas Tsao52%
→ $35Reiterates → BuyGet Alert
01/09/2023Buy Now211.63%SVB Leerink
Thomas Smith33%
$40 → $45MaintainsOutperformGet Alert
12/19/2022Buy Now211.63%Needham
Serge Belanger70%
→ $45Initiates → BuyGet Alert
12/16/2022Buy Now253.19%Credit Suisse
Tiago Fauth42%
→ $51Initiates → OutperformGet Alert
12/01/2022Buy Now142.38%HC Wainwright & Co.
Douglas Tsao52%
→ $35Initiates → BuyGet Alert
11/15/2022Buy Now218.56%JMP Securities
Jason Butler55%
$47 → $46MaintainsMarket OutperformGet Alert
08/16/2022Buy Now177.01%Ladenburg Thalmann
Michael Higgins47%
$33 → $40MaintainsBuyGet Alert
08/15/2022Buy Now177.01%SVB Leerink
Mike Kratky64%
$32 → $40MaintainsOutperformGet Alert
06/23/2022Buy Now73.13%B. Riley Securities
Kalpit Patel38%
→ $25Initiates → BuyGet Alert

FAQ

Q

What is the target price for Viridian Therapeutics (VRDN) stock?

A

The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by Needham on January 7, 2025. The analyst firm set a price target for $38.00 expecting VRDN to rise to within 12 months (a possible 163.16% upside). 32 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Viridian Therapeutics (VRDN)?

A

The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by Needham, and Viridian Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Viridian Therapeutics (VRDN)?

A

There is no last upgrade for Viridian Therapeutics

Q

When was the last downgrade for Viridian Therapeutics (VRDN)?

A

The last downgrade for Viridian Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from N/A to $27 for Viridian Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Viridian Therapeutics (VRDN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

Q

Is the Analyst Rating Viridian Therapeutics (VRDN) correct?

A

While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $38.00 to $38.00. The current price Viridian Therapeutics (VRDN) is trading at is $14.44, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch